Area of research
Hematology · Immunology
Research interest
Research interests include Acute Myeloid Leukemia Research, Immune Cell Function and Interaction, Hematopoietic Stem Cell Transplantation, and Chronic Myeloid Leukemia Treatments.
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with <i>FLT3</i>-mutated (<i>FLT3</i>mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial